AACR 2022 | Improving our understanding of CAR-T therapy to avoid T-cell exhaustion
Zinaida Good
• 12 Apr 2022
Zinaida Good, PhD, Stanford University, Stanford, CA, discusses the need to better understand which features and phenotypes are the most beneficial in a CAR-T cell product to avoid T-cell exhaustion. Dr Good highlights the diversity in CAR-T products and a study which investigated CAR-T cells at the clonal level, and concludes by explaining how reverse fate mapping of CAR-T cells helps researchers and clinicians better understand the application of CAR-T therapy in various malignancies. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
